



Annex

Presentation Slides

The Ajinomoto Foundation/ Sysmex Corporation/ NEC Corporation



Cross-industry collaboration project to improve maternal and child health and nutrition in the Republic of Ghana

August 20, 2025

The Ajinomoto Foundation

Sysmex Corporation

NEC Corporation



Ghana Nutrition Improvement Project (GNIP) by The Ajinomoto Foundation

Kaoru Kurashima
Chairman
The Ajinomoto Foundation



Nutritional issues in Ghana

THE
AJINOMOTO
FOUNDATION

Approximately 25% of two-year old children suffer from **stunting**



Nutritional quality of local weaning foods contribute to deficiencies (proteins, micronutrients, etc.)



koko
(Porridge made from fermented maize flour)

3

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Ghana Nutrition Improvement Project (GNIP)

THE
AJINOMOTO
FOUNDATION

Phase 1: Product development (2009-2012)

1. Concept

- Nutritional supplement for traditional complementary foods
- Delicious for children, improve nutrition, and prevent stunting
- Acceptable, Affordable, Accessible



2. Ingredients

Soybean, sugar, palm olein, lysine (amino acid), vitamins, micronutrients


3. Local Food Value Chain

- Local ingredients (Soy)
- Local production (Yedent)
- Local sales (ESM)



Phase 2: Building evidence (2013-2015)

Confirmed efficacy and opportunity through science-based evidence under collaboration



4


(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Ghana Nutrition Improvement Project (GNIP)

THE
AJINOMOTO
FOUNDATION

Phase 3: Collaboration with Ghana Health Service and expansion of the project (2016 -)

Through nutritional education by **staffs in health centers** and activities to introduce KOKO Plus®, build a social business model through **public-private partnerships**, aiming to create **behavioral changes in mothers and children**



5

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Renewal of MOC for further collaboration

THE
AJINOMOTO
FOUNDATION

- Improve child nutrition, reduce stunting and anemia among children aged 6 months to 10 years old, and eventually expand to other life stages and generations in Ghana.
- Train health workers in best practices for maternal and child nutrition.
- Strengthen distribution systems for nutritious foods and supplements, such as Protein and Micronutrient Powder.
- Promote dietary diversity and develop stronger, more resilient food systems.



HEALTH

GHS, KOKO Plus, TAF Strengthen Efforts to Enhance Infant Nutrition in Ghana

April 26, 2025 / GNA

By Samira Larbie/Muniratu Issah

6

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

New package design

THE
AJINOMOTO
FOUNDATION



7


(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Project framework

THE
AJINOMOTO
FOUNDATION

sysmex

NEC
Orchestrating a brighter world



8

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Dissemination of diagnostics technology which contributes to the early detection and treatment of anaemia and malaria

Sysmex Corporation
Sysmex West and Central Africa

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Innovation on malaria diagnosis

Current malaria testing



There are testing and accuracy issues, etc.

15-30 minutes required including preparation

Sysmex's innovation

- Only one minute for measurement
- Automatic analysis of **Malaria-infected RBC** with high accuracy
- +
- Screening for **anaemia**



Support for early diagnosis and early treatment for malaria and anaemia through high-quality testing


Dissemination of diagnostic technologies for the early detection and treatment of anemia and malaria




Onwe Government Hospital



Ejisu Government Hospital



Kwaso Health Centre



11


(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Collaborative research with Ghana Health Service



Analyzing and visualizing the prevalence of anaemia and malaria across specific population groups

Comprehensive analysis of Anaemia and Malaria



Dashboarding XN-31 results

Co-occurring status of anaemia and malaria

Classified anaemia patients into three types

- Microcytic anaemia
- Normocytic anaemia
- Macrocytic anaemia

*Patient categories:
 • Children under 5 years old
 • School-aged children (5~14 yrs old)
 • Pregnant woman
 • Non-pregnant woman (15-49 yrs old)

- ✓ Optimal treatment to Anaemia and Malaria patient
- ✓ Appropriate distribution of Iron supplements

Scientific Symposium: Sysmex, NEC and Ajinomoto Foundation (3rd Oct, 2024)

A Multi-sectoral Project to Improve Maternal & Child Health and Nutrition in Ghana



12

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Digital Health Checkup Mobile App for nutrition improvement and job aids

NEC Corporation

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Digital Health Checkup Mobile App in Ghana


App for improving maternal and child nutrition and job aids for health workers



The value of NEC's application

NEC

\Orchestrating a brighter world




15

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation

Application Image



NEC

\Orchestrating a brighter world



16

(c) 2025 The Ajinomoto Foundation/Sysmex Corporation/NEC Corporation





Annex

Presentation Slides

Shionogi & Co., Ltd.



Fight against Antimicrobial Resistance (AMR) in Africa

Takuko Sawada

Vice Chairperson
Shionogi & Co., Ltd.

1



SHIONOGI Group Heritage

SHIONOGI strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve.

Established	1878
Headquarters	Osaka, Japan
Type of Business	R&D, Manufacturing and distribution of pharmaceuticals, diagnostic reagents and medical devices, etc.
Number of Employees	Consolidated : 4,955*
Revenue	JPY 438,268M*
Operating Profit	JPY 156,603M*



Freedom from the threat of infectious diseases




²

*As of 31st March 2025



Antimicrobial Resistance (AMR) : One of the Top Global Health Threats




Source: The Lancet 2022, Vol. 399, 629–55 ([Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis - The Lancet](#))



Impact of AMR is heaviest in Sub-Saharan Africa

AMR-associated deaths per 100 000 population



Source: The Lancet online infographic, May 2024 ([antibiotic-resistance-printable-1720780640950.pdf](#))



But Challenges for Accessing Antibiotics Remain

DEVELOPMENT and DELIVERY

- Need for healthcare infrastructure development
- Hurdles for conducting clinical trials (diagnosis, patient enrollment, differences in regulatory)
- Product use needs to be monitored and restricted to avoid resistance development
- Complex manufacturing and difficulty of discharge control

ACCESS

- Complex management of local regulations; need to ensure proper pharmacovigilance and compliance
- Complicated, unstable supply chain; potential for diversion
- Challenges associated with appropriate use and stewardship under a variety of healthcare settings
- Limited guidance and training on stewardship and appropriate use
- Complex economics from buyer and supplier sides


- ✓ Cefiderocol is a novel siderophore cephalosporin that effectively penetrates the outer membrane of Gram-negative pathogens
- ✓ Its inclusion in the WHO Model List of Essential Medicines highlights its global therapeutic value
- ✓ As the only medicine prequalified by WHO for AMR infectious diseases, cefiderocol stands out in the fight against drug-resistant pathogens.

5




SHIONOGI's Collaboration to Expand Access: Early Access

- In June 2022, SHIONOGI began a collaboration with GARDP and CHAI to supply cefiderocol to LMICs.
- SHIONOGI grants GARDP non-exclusive rights to commercialize cefiderocol in 135 countries.
- GARDP sublicenses to a generic manufacturer to ensure quality production and fair pricing.
- Manufacturing and commercial sublicensees supply cefiderocol to countries committed to appropriate use.
- SHIONOGI, with facilitation by CHAI, provides technical transfer to support generic production.



6



SHIONOGI's Collaboration to Expand Access: Early Access

Notice 2025/07/18

Submission of Letter of Intent and Concept Note to the Kenyan Ministry of Health to Accelerate Access to Cefiderocol

July 18, 2025 - Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; hereinafter, "Shionogi"), in collaboration with the Global Antibiotic Research & Development Partnership (Head Office: Geneva, Switzerland; hereinafter "GARDP"), has agreed to collaborate with the Ministry of Health of the Republic of Kenya (hereinafter, "Kenya") on a project aiming to facilitate the introduction of cefiderocol, a treatment for serious Gram-negative bacterial infections in adults with limited treatment options, in the country. Shionogi and GARDP submitted to the Kenyan Ministry of Health a Letter of Intent and a project Concept Note, which were subsequently accepted.


The project proposes to support the appropriate use of cefiderocol in select tertiary hospitals through a phased approach that aligns with the Kenyan Ministry of Health antimicrobial stewardship framework and national AMR priorities. This project will be a collaborative effort between Shionogi, GARDP, the Kenyan Ministry of Health, and other Kenyan stakeholders, and it will generate critical insights to inform broader access strategies for Kenya and beyond.

One of Shionogi's key material issues is to "Improve Access to Healthcare". Shionogi is committed to strengthening collaborative initiatives with domestic and international partners, contributing to the development of a sustainable society.^{1,2} These efforts include improving access to antimicrobial treatments* and supporting maternal and child health programs in Africa.** As a global leader in infectious disease treatment, Shionogi continues to actively address a wide range of public health challenges, including some of the world's major infectious diseases, such as AMR and COVID-19.



7

SHIONOGI's Collaboration to Expand Access: Antimicrobial Stewardship



Industry-academia partnership agreement concluded to support antimicrobial stewardship systems in healthcare institutions in Kenya, while also aiming to expand healthcare initiatives across other African countries and regions.



8

SHIONOGI's Collaboration to Expand Access: Antimicrobial Stewardship

Potential activities of the four-party partnership agreement include:

- ✓ Launch and implementation of joint research projects related to AMR in Kenya

(Promotion of surveys and research related to AMR in Kenyan healthcare institutions)

- ✓ Human resource development in infectious disease control

(Training of future AMR leaders through education on infection control and appropriate antimicrobial use for Kenyan healthcare professionals)

Strengthening AMR countermeasures in Kenya while also aiming to expand healthcare initiatives across other African countries and regions, and to contribute to the AMR issue in Africa and globally

9



Visit us at TICAD9 Japan Fair!

Date: until 22nd August
Organized by: JETRO and JBCA
Sponsored by: METI and MOFA, Japan
Venue: Pacifico Yokohama Halls B and C

SHIONOGI booth:
B18



10



Mother to Mother SHIONOGI Project



■ Project Overview

Vision

To develop sustainable communities for the well-being of mothers and children.

Goal

- Improving health of pregnant and lactating women and health of children under 5 years of age
- Establishment of sustainable community health systems



11

■ Three pillars of activities



Improvement of infrastructure



Education and sensitization



Enhancement of the community support system

■ Third Term Project



Thank you for your attention!

12



Appendix: Partners and our Strengths

<p>Nagasaki University is one of Japan's leading centers for infectious disease education and research. Its Department of Infectious Diseases and Infection Control Education Center actively supports infection care and control both within and beyond the hospital. Through this initiative, it contributes to infectious disease training and human resource development by offering clinical training to healthcare institutions.</p>	<p>Connect Afya Ltd. (Afya means "Health" in Swahili) is a Japanese startup that operates clinical labs, medical device distribution, and clinics in Kenya. In July 2024, it opened one of East Africa's largest integrated labs in Nairobi, offering services from health screenings to next-generation sequencing. Through this project, Connect Afya supports healthcare facilities in building diagnostic systems essential for appropriate antibiotic use.</p>
<p>Comprehensive Partnership</p>	
<p>Saraya Co., Ltd. builds its business around three pillars: hygiene, environment, and health, aiming to create a more sustainable and prosperous global society. Since 2014, it has locally produced and sold alcohol-based hand sanitizers in Uganda. Drawing on its experience in infection control training in Kenya and other regions, Saraya supports healthcare facilities in strengthening infection prevention systems to help combat AMR through this initiative.</p>	<p>Shionogi & Co., Ltd. has identified "Improving Access to Healthcare" as one of its material issues and is actively strengthening collaborative efforts to contribute to the realization. These efforts include improving access to treatment for antimicrobial resistance (AMR) and supporting maternal and child health initiatives in Africa.</p>



Annex

Presentation Slides

Sunda Technology Global Co., Ltd.



Prepaid water meter for public water facilities



Sunda Technology Global
Sunda Technologies Uganda



Mission & Vision

SUNDA

Mission

Achieving safe water access for all the people in Africa

- Targeting water as the key element of infrastructure
- Assuring safe water for everyone

Vision

Build a Self-sustaining Operation & Maintenance system

- Building a mechanism for sustainable Operation and Maintenance (O&M)
- Creating a system that enables easy and continuous payment for water





Hand pump



Public Tap Stand





Collecting money **by Cash**

- Mentally and physically demanding
- Resignation of caretaker



Misuse of funds

- Loss of trust for caretaker
- Discouragement for payment



Sense of Unfairness

- Free riders
- Seasons: dry/rain
- Different size of families

Prepaid & Automated water fee collection system



- **SUNDA unit** installed on existing/new handpump



Load Water by
Mobile Money



Insert the Tag



Fetch Water

- Fetched water amount is deducted from the Tag
- Water is charged per Liter

Before SUNDA (~2018)



- **Broken handpump** remained unrepaired for **months or even years** due to lack of funds.
- This often **caused conflicts** over who should pay for repairs.
- People relied on **dirty pond water for daily use**, leading to widespread **diarrhea**.
- Some girls were raped on the way to collect water, became pregnant, and dropped out of school.

After SUNDA (2019~)

- Handpumps are now repaired within **a day or just a few days**.
- SUNDA enables regular fee collection—**about 150,000 ugx per month on average**, which is sufficient for sustainable maintenance.
- People now use **clean water from the handpump every day**.
- Using dirty pond water is a thing of the past—**many young children don't even know such ponds existed**.



SUNDA: Prepaid & Automated water fee collection system.

[SUNDA for public tap]



Experience in the field

SUNDA



District Meeting 10+

- Introducing the project to CAO and DWO
- Getting cooperation and information on water sources



Sub-county Meeting 30+

- Introducing the project to local leaders
- Getting understanding for the project
- Getting cooperation for community sensitization



Community Sensitization 300+

- Introducing SUNDA to community people
- Getting understanding and agreement on SUNDA installation



SUNDA Installation 300+

- Installing SUNDA
- Repairing boreholes if necessary

Collaboration between Uganda & Japan

SUNDA



Sunda Engineers/Co-founders

Understanding local needs and designing solutions tailored to the local context



36 engineering companies in Kyoto, Japan

Technical assistance to transform Ugandan innovations into mass-produced products



SUNDA to all across Africa, to solve water problems.

2030~

**1 million of
water facilities
in Africa**

~2023

2025

【Previously】

- Needs analysis
- Trust building
- 150 units installed

【Now】

- Mass production
- Expand SUNDA all across Uganda and neighboring countries

with our PARTNERS

Booth A45

@Japan Fair

*Build a sustainable O&M and
achieve continuous safe water access*

Aya Tsuboi
+256 756759251
aya@sundaglobal.com

SUNDA: Prepaid & Automated water fee collection system

SUNDA

Hand Pump



[SUNDA Unit]

- ① SUNDA unit installed on existing/new handpump
- ② An ID tag for each household
- ③ Water can be loaded via mobile money
- ④ Water is charged per Liter



*Locally developed and
Manufactured system
by Ugandan engineers*

How Sunda Works

SUNDA

ID tag

Each household has an ID tag



Payment

Pay for water through mobile money
*217*288# [25sh/20L]



Fetch water



[LED indicator]

- Green: Operating
- Blue: more than 200L
- Orange: 20L-200L
- Red: less than 20L

[Tag reader]


[Orange Box]

- Water meter
- Valve
- Motherboard
- Battery
- Charger controller

Pumping

When the ID is charged
Water comes out

When the ID is NOT charged
Water does not come out



[Dashboard]

- Water usage
- Payment



[SUNDA for public tap]

Benefit of SUNDA

- ① **Easy water access even for children**
— Just tap an ID tag
- ② Safe water **accessible 24/7**
- ③ No more troubles with attendants
— **Revenue has increased**
- ④ **Stable and sustainable operation**
for facility owners



Without SUNDA

= Water fee collection **by an attendant**

Issues

- ① Misuse of Funds
- ② Absent Attendants
- ③ Uncontrolled Water Prices

Many public taps are abandoned!



With SUNDA

= **Automated** Water fee collection

Issues Solved

- ① No more, Misuse of Funds
- ② 24/7 Water Access
- ③ Water Prices

Stable and sustainable operation

History

SUNDA

JICA volunteer



2018

Sunda founded



2020

Pilot under
JICA project



2021-22

Expansion &
SUNDA tap started



2024-





Annex

Presentation Slides

TWINBIRD Corporation





Co-Creating the Future of Healthcare and the Economy:
Japan-Africa Public-Private Partnerships at the Forefront

@TICAD9

August 20th, 2025

Salvage from Coronavirus Threat

12,000 units were used across Japan without break-down!



Vaccine
Producers



Import



Country
Level




Distribution
Level



Service Point



We are TWINBIRD from Tsubame-Sanjo in Niigata, Japan



Company Name	TWINBIRD CORPORATION
Start of operations	1951
Inauguration	1962
Capital	JPY 100 million
Net sales	JPY 10,300 million
Business sector	Manufacture and sale of home electric appliances, etc.
Number of employees	300
Market listing	Tokyo Stock Exchange (Standard Market)



3



Integrated Technology from Tsubame-Sanjo Made It Happen

FPSC = Free Piston Stirling Cooler

- Cools down as low as -100 deg C
- Controls temp. +/- 1 deg C
- Compact, all-in-one (40cm height)
- Vibration resistant
- Off freon refrigerant
- Consumes less energy
- Flexible in power source – DC/AC/car plug



TWINBIRD --- only 1 FPSC manufacturer in the world for industrial use

4



Not only in Japan but to the World

- Participated in the “LAST ONE MILE” campaign through MOFA/JICA
- Our freezers were delivered to Mongolia, East-Timor, Palestine, Mozambique, and Senegal



Presentation Ceremony



Middle of Transportation



Delivered Countries

5



What Could We Expect?

Table 3: Recommended vaccine storage temperatures/times for different levels of the cold chain

Vaccine	Republican SES (National)	Regional SES (Oblast)	District SES (Rayon)	Health Facilities
Maximum Storage time	up to 6 months	up to 3months	up to 1 month	up to 1 month
OPV	-15 to -25°C	-15 to -25°C	-15 to -25°C*	0 to +8°C
Measles	-15 to -25°C	-15 to -25°C	-15 to -25°C*	0 to +8°C
Mumps	-15 to -25°C	-15 to -25°C	-15 to -25°C*	0 to +8°C
DPT	0 to +8°C	0 to +8°C	0 to +8°C	0 to +8°C
Hep B	0 to +8°C	0 to +8°C	0 to +8°C	0 to +8°C
DT	0 to +8°C	0 to +8°C	0 to +8°C	0 to +8°C
Td	0 to +8°C	0 to +8°C	0 to +8°C	0 to +8°C
TT	0 to +8°C	0 to +8°C	0 to +8°C	0 to +8°C
BCG	0 to +8°C	0 to +8°C	0 to +8°C	0 to +8°C



Capacity : 25L

Set Temp. : -40~+10 deg C


Safe vaccine handling, cold chain and immunizations, prepared by WHO/UNICEF
https://iris.who.int/bitstream/handle/10665/64776/WHO_EPI_LHIS_98.02.pdf?sequence=1

6



Where Could We Expect?

E5 Preventive maintenance (2009-2020)



Source: Effective Vaccine Management Global Data Analysis


https://cdn.who.int/media/docs/default-source/immunization/supply-chain/evm-global-data-analysis-2009-2020.pdf?sfvrsn=9113352_11



7

Where Could We Expect?

E6 Stock management (2009-2020)



Source: Effective Vaccine Management Global Data Analysis

https://cdn.who.int/media/docs/default-source/immunization/supply-chain/evm-global-data-analysis-2009-2020.pdf?sfvrsn=9113352_11



8

Now WHO Admits Us

PQS Certified in October 2024 – adopted an initiative by MHLW*



Product ID	Product Name	Manufacturer	Model	Download PDF	Copy link
E003/139	Icelined Refrigerator	MFG. Co. Ltd.	GHR 150 AC	Download PDF	Copy link
E003/140	Transportable vaccine storage device	EMK TEC GmbH	Indigo 201	Download PDF	Copy link
E003/141	Vaccine Freezer	Twinbird Corporation	SC-DF25P Deep FreezerP	Download PDF	Copy link

Source:
https://apps.who.int/immunization_standards/vaccine_quality/pqs_catalogue/categorypage.aspx?id_cat=17



SC-DF25P

* WHO pre-certification and recommendation acquisition and promotion project for listing in the WHO recommended equipment directory for emerging countries



9

WE ARE LOOKING FOR COLLABORATIVE PARTNERSHIP

Drop by the BOOTH #B20

Thank you

Merci

Obligado

Asante

Dankie

ありがとう





Annex

Presentation Slides

FUJIFILM Corporation





Forging a Healthier Future: Fujifilm's Activity to Africa

A Japan-Africa Partnership for Innovation in Healthcare

August 20, 2025

FUJIFILM Holdings Corporation

Shin Tagawa
Managing Director
Fujifilm Middle East and Africa



**Let's team up
for TICAD9!**

20-22 August 2025 PACIFICO YOKOHAMA

Company Profile



As of June 30, 2025

Company profile

Company Name	FUJIFILM Holdings Corporation
Representative	President and CEO, Representative Director Teiichi Goto
Date Established	January 20, 1934
Fiscal year-end	March 31
Capital	¥ 40.4 B (As of March 31, 2025)
Consolidated Revenue	¥ 3,195.8 B (FY2024)
Net Income <small>(Attributable to FUJIFILM Holdings)</small>	¥ 261.0 B (FY2024)
Number of Group Companies	270 (As of March 31, 2025)
Consolidated Employees	72,593 (As of March 31, 2025)

Stock Information

Stock Code	4901
Stock Exchange Listings	Tokyo
Minimum Trading Units	100
Number of shares issued	1,243,877,184 <small>(FY2024)</small>
Authorized Number of Shares	2,400,000,000 <small>(FY2024)</small>
Ordinary General Meeting of Shareholders	The end of June
End-of-term registration deadline for dividend payment	March 31
Mid-term registration deadline for dividend payment	September 30
Shareholder Registry Administrator	Sumitomo Mitsui Trust Bank, Limited

*The Company conducted a stock split as of April 1, 2024 at a ratio of three shares for one common stock.



KENJI SUKENO
Chairman, Representative Director and Board Chairman,
FUJIFILM Holdings Corporation



TEIICHI GOTO
President and Chief Executive Officer,
FUJIFILM Holdings Corporation

Corporate Philosophy

We will use leading-edge, proprietary technologies to provide top-quality products and services that contribute to the advancement of culture, science, technology and industry, as well as improved health and environmental protection in society. Our overarching aim is to help enhance the quality of life of people worldwide.

Vision

Anchored by an open, fair and clear corporate culture and with leading-edge, proprietary technologies, Fujifilm is determined to remain a leading company by boldly taking up the challenge of developing new products and creating new value.

Corporate Slogan

Value from Innovation

 270 Companies worldwide	 72,593 Employees worldwide	 \$ 22 billion* Global revenue	 \$ 7.5 billion* Global healthcare revenue
-----------------------------	--------------------------------	-----------------------------------	---



Approx. \$7.5B

POST TEST

¥ 542.0B 17.0%

- | | |
|----------|----|
| ¥ 328.08 | 61 |
| ¥ 214.08 | 39 |



¥ 1,198.5B 37.5%

- | | |
|----------|-----|
| ¥ 330.9B | 26% |
| ¥ 522.9B | 44% |
| ¥ 344.7B | 28% |



¥ 1,022.6B 32.0%

- | | |
|----------|-----|
| ¥ 693.2B | 68% |
| ¥ 219.5B | 21% |
| ¥ 109.8B | 11% |



¥ 432.8B 13.5%

- | | |
|----------|-----|
| ¥ 250.4B | 58% |
| ¥ 182.4B | 42% |



PREVENTION

TOTAL HEALTHCARE COMPANY

DIAGNOSIS


TREATMENT



Fujifilm Middle East and Africa

Fujifilm's three-pillar approach to healthcare transformation in Africa

Our Strategy: Sustainable Impact Through Partnership



Empowering People: Advancing The Standard of Healthcare Provision



The Fujifilm Academy - Egypt

The Fujifilm Academy in Egypt exemplifies our commitment to sustainable healthcare development through knowledge transfer and professional training.

In partnership with Egypt's Ministry of Health, UPA, Radiographer Society and leading universities, we established the Fujifilm Academy to deliver hands-on training and education.



Fujifilm Middle East and Africa

Tackling the Doctor Shortage: The "Takumi" Project



The Challenge

Critical shortage of trained endoscopists across Africa:

- 1 endoscopist per 470,000 people in Africa
- Compared to 1 per 7,000 in Japan

Our Solution

The "Takumi" (Master Craftsman) Project:

- Advanced, AI-assisted endoscopy training
- Collaboration with Japanese medical universities

Taking Action

Partnership with R0, a Japanese medical simulator manufacturer, to provide advanced technical training with the "Mikoto" endoscopy simulator



Fujifilm Middle East and Africa

Empowering Senegal Partnership: 2024-2025

Invitation of endoscopic surgeons from Senegal to Japan for specialized training at Jichi Medical University



From Training
2024 → 2025
To MOU Signing




This partnership represents a sustainable model for healthcare capacity building that can be replicated across other African nations, creating centers of excellence for endoscopic training.

Fujifilm Middle East and Africa

9 FUJIFILM

Innovating for Access: The Fight Against TB

FUJIFILM
Value from Innovation



Stop TB Partnership



Fujifilm Middle East and Africa

The Global Fund
To Fight AIDS, Tuberculosis and Malaria



BILL & MELINDA GATES foundation



FUJIFILM

Driving Digital Transformation

National Project

Digitalized entire public healthcare network in Namibia


Collaborate with Namibia's Ministry of Health
to digitalize and connect the Radiology departments in

48 hospitals & Clinics across the country

With Synapse PACS, RIS, Synapse 3D, with Tele-Radiology platform & Artificial Intelligence



Fujifilm Middle East and Africa



FUJIFILM

Our commitment to the world

FUJIFILM
Value from Innovation

Fujifilm Group's Purpose

Giving our world more smiles

We bring diverse ideas, unique capabilities,
and extraordinary people together to change the world.

FUJIFILM
Value from Innovation

13



Annex

Presentation Slides

Terumo Corporation



Establish SCD as a public health priority in sub-Saharan Africa

Head, Patient Access, Africa
Terumo BCT Kenya Ltd.

Nathan Mulure, MD



August 20th, 2025



Terumo Was Founded by Medical Scientists

1921

With the intention of manufacturing the most reliable clinical thermometer possible, Terumo Corporation was founded by several medical scientists including Dr. Shibasaburo Kitasato.



The origin of the company name

Terumo comes from the German word,
“Thermometer”

Terumo's company charter and thermometer at the time of establishment



Dr. Shibasaburo Kitasato
(1853 -1931)

- Discovered the immune antibody against the tetanus toxin and established a serum therapy for tetanus.
- Identified a plague bacillus and paved the way for preventive medicine.
- Featured on the Japanese bank note (1,000-yen bill) from 2024.

Terumo Group Mission

Contributing to Society through Healthcare

Medical Care
Solutions Company



Blood and Cell Technologies
Company



Cardiac and Vascular
Company



| Global Blood Solutions | Therapeutic Apheresis | Cell Therapy Technologies |

©TERUMO CORPORATION

TERUMO

Delivering Our Products and Services Around the World

Fiscal year ended March 2025



Business in
over **160**
countries and regions



Number of
consolidated
subsidiaries **99**



Number of associates
Terumo Group **30,689**
Terumo Corp. **5,633**




Number of products
More than
52,000



Number of R&D bases
Japan **6**
Outside of Japan **16**



Number of
production bases
Japan **7**
Outside of Japan **22**



Revenue (consolidated)

1.04T JPY

Overseas Revenue Ratio: **79%**


The percentage of revenue composition is rounded to the nearest whole number, and the total may not equal 100%.

©TERUMO CORPORATION

TERUMO

SICKLE CELL DISEASE

- Most common genetic disorder in Africa
- 300,000 new births globally, 90% are in Africa
- Nigeria, Congo DRC, Uganda are some of the high burden countries
- 150,000 new births in Nigeria every year.
- 30,000 new births in Uganda
- 14,000 new births in Kenya




<https://www.datelinehealthafrica.org/sickle-cell-disease-essential-information-for-africans>

©TERUMO CORPORATION

TERUMO

SCD Pathology: A Genetic Blood Disorder



©TERUMO CORPORATION

TERUMO


SCD Pathology: A Genetic Blood Disorder



©TERUMO CORPORATION

TERUMO


SCD is a Systemic Disease with Pain being the hallmark



©TERUMO CORPORATION

TERUMO

Public Health in Africa – Main Causes of Child Mortality*



Causes of Child Mortality	Kenya	Uganda	Ivory Coast
Acute Lower Respiratory Infections	14%	11%	14%
Congenital Anomalies	7%	6%	4%
Infectious Disease	19%	24%	34%
Diarrhoeal Diseases	7%	5%	9%
HIV/AIDS	2%	3%	1%
Malaria	5%	11%	19%
Measles	0%	0%	0%
Meningitis / Encephalitis	2%	2%	2%
Tetanus	0%	0%	3%
Tuberculosis	3%	2%	1%
Injuries	6%	5%	4%
Newborn	38%	34%	31%
Birth Asphyxia and Birth Trauma	14%	12%	11%
Prematurity	21%	19%	18%
Sepsis and Other Infectious conditions of Newborn	3%	3%	3%
Others	16%	20%	13%

Sickle Cell Disease is not yet priority in Africa

* World Health Organization – Number of under Five Death by cause
<https://www.who.int/data/maternal-newborn-child-adolescent-ageing/indicator-explorer-new/mca/number-of-under-five-deaths---by-cause>

©TERUMO CORPORATION

TERUMO

Solving the problem



SCD is a Neglected Disease of Public Health Concern in Africa

Multi-stakeholder groups engaged in multiple discussions to address this challenge in three African countries



©TERUMO CORPORATION

TERUMO

Pilot project



Côte d'Ivoire, Gbêkê



4.9% of Country Population

Kenya, Kakamega



Kenya, Taita Taveta



1.2% of Country Population **0.7%** of Country Population



Uganda, Jinja



1.3% of Country Population

©TERUMO CORPORATION



Goal: Establish a Comprehensive SCD Care Pathway



1. PRIMARY INTERVENTIONS

- 1.1. Awareness
- 1.2. Screening
- 1.3. Sustainable Linkage to Care
- 1.4. Prevention



2. SECONDARY INTERVENTIONS

- 2.1. Laboratory & Imaging Diagnostics (Screening + Routine Tests)
- 2.2. Supportive, Prophylactic & Disease Modifying Therapies



3. TERTIARY INTERVENTIONS

- 3.1. Acute Care
- 3.2. Chronic Care
- 3.3. Curative therapy



| Medical Supply Chain (Medicine, Blood, Testing)|




| Advocacy | Training | Monitoring & Evaluation Plan (M&E) | Financial Governance (costing, funding, reimbursement) |

©TERUMO CORPORATION



Fundraising Activities



Pilot proposals/Objectives must be feasible, well articulated, and formally documented to convince funders:

- Industry
- NGOs, Governments
- Local MoH

To secure funding for the pilot project, it will require project writing, project planning, and grant writing

Terumo Corporation applied for METI subsidy to support the Project



©TERUMO CORPORATION

TERUMO

TERUMO



Annex

Presentation Slides

**MOL Logistics Co., Ltd. /
Revital Healthcare (EPZ) Ltd.**



August 20, 2025

Establishing an African Healthcare Supply Chain through the Logistics Hub in Dongo Kundu SEZ at Mombasa Port, Kenya

MOL Logistics Co., Ltd
(Director, Chairman) Koichi Yashima

Revital Healthcare (EPZ) Ltd.
(Director, Business Development) Harsh Mehta



1-1. MOL Group



3

1-2. MOL Activity Map in Africa



MOL History in Africa

Africa Route
opened in
1916



1st ship in Africa Route
"Canada Maru"

Cape Town Office
opened in
1918



Africa Route Map in 1926

Mombasa Office
opened in
1929



Pre-war Mombasa Resident Office
(1929-1941)

4

1-3. MOL Logistics



Corporate History 1960 - 1970

Established as Mitsui Line Air Service Co., Ltd.

The company was renamed to Mitsui Line Air Service Co., Ltd.

1960

1961

Accredited as an IATA cargo agent

1964

1973

Obtained license for air freight forwarding (consolidation services)

Corporate History 1980 - Present

Mitsui Air & Sea Service Co., Ltd. and Shosen Air & Sea Service Co., Ltd. Merged to form M.O. Air System, Inc.

The company was renamed "MOL Logistics Co., Ltd."

Commencement of warehouse operations in Nairobi

1989

2001

The company was split and reestablished as an international logistics business.

2001

2017

Establishment of Nairobi Office

2023

July

2024

Strategic Partnership with Revital to Enhance Healthcare Transportation

Company Profile

Company Name	MOL Logistics Co., Ltd.
Head Office	1-2-2 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011 Hibiya Daibiru Building TEL: +81-3-6731-7500 FAX: +81-3-6837-5701
Capital	750 million yen (authorized capital: 1.8 billion yen) Shareholder: Mitsui O.S.K. Lines, Ltd. (100%)
Number of Employees	3,300 employees (as of March 2025)
Consolidated Revenue	JPY 87.6 billion (fiscal year ended March 2025)

1-4. MOL Logistics



Air Shipment

Our air freight services cover charter and freighter arrangements, handling everything from large to urgent small shipments. Door-to-door delivery is available to ensure fast and seamless transportation.



Ocean Shipment

We offer a full range of ocean freight solutions, including LCL, FCL, and conventional vessel shipments. With experience in various cargo types and cross-trade shipments, we provide flexible and reliable services worldwide.



International Moving

As a pioneer in international moving, we offer one-stop support for overseas assignments, returns, and cross-border relocations, backed by extensive experience and a global network.



Logistics

We offer packing, storage, customs clearance, and insurance, as well as cross-border and multimodal integrated transport, with full support for various ancillary services and all transport modes.





2-1 Revital®

Who we are and our story so far

17 Years


Factory in **Mombasa, Kenya** inaugurated by H.E Honi Mwai Kibaki (Former President of Kenya)

Only manufacturer in Africa to make **blood collection tubes**

Completed **current facility**, allowing for expansion of product range

At full capacity of **~18 medical devices annually** with catalogue of **40+ products** exported to **20+ countries**

Received funding from **USAID** to scale-up manufacturing of RDT's



LARGEST MANUFACTURERS OF MEDICAL DEVICES IN AFRICA

Operational Markets

17 Years

Revital Operations



EXPORTING TO
40+ COUNTRIES



MANUFACTURING
300 SKU'S



WHO-PREQUALIFIED
10 SYRINGES



650+ EMPLOYEE'S
80% FEMALE



2.1 Billion

Annual Manufacturing Capacity for Medical Devices

Global Partners



9

Mombasa (Dongo Kundu SEZ) Warehouse Project




3-1. Supply Chain Revolution

The establishment of a healthcare logistics hub in Mombasa will revolutionize the supply chain through storage, kitting and dispatch of healthcare kits and products from Kenya to the rest of Africa...




3-2. Multiple Functions in Warehouse

The logistics facility would serve key business functions to ensure an end-to-end service for the development of **healthcare security** on the African continent while accommodating warehousing, storage and supply for all other business sectors...



3-3. Example (Vaccine Delivery)

CREATING A SOLUTION FOR VACCINE DELIVERY FOR AFRICA



3-4. Potential Expansion

We aim to continue developing the Dongo Kundu project by attracting **global medical machine manufacturers** to establish the **final assembly of products** in Kenya to improve the market accessibility of high-value medical machinery in Africa.

